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Since the introduction of recombinant human growth hor-
mone (GH) in in the mid-1980s, supplies are almost limit-
less and predictably GH usage has escalated dramatically.
There have been more than 150,000 children treated with
GH worldwide with a wide variety of growth disorders.
Adverse events (AE) with all forms of drug therapy are
markedly under-reported, considerably underestimating
the incidence of the AE. This under-reporting occurs
even when the AE is serious and has a possible or prob-
able association with GH therapy. Careful audit of the
frequency of reporting of severe AE to other drugs with a
possible or probable association with treatment is only
14%. Furthermore missing data is very common and adds
to the difficulty in interpreting AE.
Important conditions (adverse events) possibly linked
to GH treatment are fortunately rare. There are several
major limitations to accurately assessing the prevalence
and risk of rare adverse events. Firstly, extremely large
datasets are required found in large databases such KIGS
and NCGS each with >50,000 enrolled patients. Secondly,
accurate risk assessment of the possible adverse event in
an untreated population that matches the GH treated
population has rarely been determined.
Important potential adverse events that have received
considerable attention will be addressed. These include;
tumour recurrence, new malignancies including leukae-
mia, diabetes mellitus, benign intracranial hypertension
and slipped upper femoral epiphyses. The physiological
rationale and the risk of these conditions during GH
treatment will be addressed.
Serum IGF-I monitoring to prevent elevated levels
that may further increase the risk of adverse events is
recommended. The potential adverse consequences of
sustained elevated serum IGF-I levels will be discussed.
In addition, monitoring IGF-I helps to monitor compli-
ance of GH therapy in children with GH deficiency.
Published: 3 October 2013
doi:10.1186/1687-9856-2013-S1-O14
Cite this article as: Cutfield: How safe is growth hormone treatment
during childhood? International Journal of Pediatric Endocrinology 2013
2013(Suppl 1):O14.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submitLiggins Institute and National Research Centre for Growth and Development.
University of Auckland, New Zealand
Cutfield International Journal of Pediatric Endocrinology 2013, 2013(Suppl 1):O14
http://www.ijpeonline.com/content/2013/S1/O14
© 2013 Cutfield; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
